Rosuvastatin is well suited for the treatment of HIV dyslipidemia as it is not metabolised by the CYP3A4 pathway, therefore, we suggest that clinicians consider a combination approach involving low dose rosuvastatin (i.e. 10 mg) in combination with either a fibrate or ezetimibe as data presented here and previously published data suggest that these combinations are effective [9,24]. The gene discussed is CYP3A4; the disease is metabolic syndrome.